Innovative therapies
for complex conditions

Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer

About Peak Bio

Experienced management team with more than 50 plus years of industry experience in small molecules, antibodies, and antibody-drug-conjugates (ADC) drug development and has successfully forged companies that create best-in-class therapeutics during their tenures.

More about Peak Bio  

PHP-303 overview


PHP-303 is a novel small molecule inhibitor of Neutrophil Elastase being investigated therapeutically for a rare and potentially life-threatening genetic condition called AATD.

Learn more about PHP-303  

Novel Toxins Cell overview

Novel Toxins

ADCs are a class of anti-cancer that combine selectivity of monoclonal antibodies with the cytotoxic potential of small molecule therapeutics and targeted therapies.

Learn more about ADCs  

Stock Information

Peak Bio, Inc.

Latest News

View all news

Remembering Patricia Finn

It is with great sadness that we share the passing of our beloved employee, Dr. Patricia Finn, PhD. on Friday December 15, 2023. Dr. Finn was an integral part of the Peak Bio Research and Development team until her last day. She will truly be missed by all.

Her family has set up a scholarship fund in lieu of service and flowers.

Patricia Finn Obituary (1958 - 2023)